Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis

Breast Cancer Research and Treatment

Volumn 100, Issue 2, 2006, Pages 177-181

  Langenegger, T ^a   Wahl, P ^b   Schiesser, D ^b   Thurlimann B ^a  

^a Senologie Zentrum Ostschweiz   (Switzerland)

^b Division of Nephrology   (Switzerland)

Author keywords

Anastrozole; Breast cancer; Hemodialysis; N desmethyl tamoxifen; Plasma levels; Tamoxifen

Indexed keywords

ANASTROZOLE; DESMETHYL TAMOXIFEN; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ANAMNESIS; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CASE REPORT; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NITRILES; RENAL DIALYSIS; TAMOXIFEN; TRIAZOLES;

EID: 33750343162     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9243-7     Document Type: Article

References (15)

1. Morello KC, Wurz GT, DeGregorio MW (2003) Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 42(4):362-372
2. Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Results of two randomised trials designed for combined analysis. Cancer 92(9):2247-2258
3. Chem Bank (2002) Global database for potentially hazardous chemicals http://www.chembank.med.harvard.edu. Cited 22 Mar 2006
4. Crewe HK, Noteley LM, Wunsch RM et al (2002) Metabolism of tamoxifen by recombinant human cytochrome p450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30(8):869-874
5. Sheth HR, Lord G, Tkaczuk K et al (2003) Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients. J Womens Health (Larchmt) 2(8):799-808
6. Guerrieri-Gonzaga A, Baglietto L, Johansson H, Bonanni B, Robertson C, Sandri MT et al (2001) Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiol Biomarkers Prev 10:967-970
7. Sutherland CM, Sternson LA, Muchmore JH et al (1984) Effect of impaired renal function on tamoxifen. J Surg Oncol 27:222-223
8. Allaria PM, Giangrande A, Gandini E et al (1999) Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol 12:395-397
9. Buzdar AU, Robertson JFR, Eiermann W et al (2002) An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 95(9):2006-2016
10. Lonning P, Pfister C, Martoni A et al (2003) Pharmacokinetics of third-generation aromatase inhibitors. Sem Oncol 30(4, Supp 14):23-32
11. The ATAC Trialist Group (2001) Pharmacokinetics of anastrazole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the "Arimidex and Tamoxifen Alone or in Combination" (ATAC) trial. Br J Cancer 85(3):317-324
12. Pastan S, Bailey J (1998) Dialysis therapy. NEJM 338(20):1428-1437
13. Remmele W, Stegner HE (1987) Vorschlag zur einheitlichen Definition eines Immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8:138-140
14. Decensi A, Gandini S, Guerrieri-Gonzaga A (1999) Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 17(9):2633-2638
15. Fagugli RM, De Smet R, Buoncristiani U (2002) Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 40(2):339-347